Detection of novel variant TMPRSS2 /ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer
Maisa Yoshimoto(University of Alberta), Maria Zieleńska(University of Toronto), Neil Fleshner(Princess Margaret Cancer Centre), Susan Chilton‐MacNeill(Hospital for Sick Children), Jane Bayani(Ontario Institute for Cancer Research), Anthony M. Joshua(St Vincent's Hospital Sydney), Antonio Finelli(University Health Network), A. Evans(Ontario Institute for Cancer Research), Joan Sweet(University Health Network), M. Prasad(Ontario Institute for Cancer Research), Jeremy A. Squire(Universidade de São Paulo)
Cited by 0
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k